Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT05860296
Title Testing Experimental Anti-cancer Drug SLC-391 With an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung Cancers
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors SignalChem Lifesciences Corporation
Age Groups: adult | senior
Covered Countries USA | CAN

No variant requirements are available.